Objective To develop core outcome sets (COS) for studies evaluating interventions for (1) prevention and (2) treatment of postpartum haemorrhage (PPH), and recommendations on how to report the COS.
Introduction
Over 250 000 women die each year from complications of childbirth. 1 Postpartum haemorrhage (PPH) is the leading cause of maternal mortality worldwide. 2 It is usually defined as blood loss of ≥ 500 ml from the genital tract within 24 hours after childbirth.
Interventions for PPH have been evaluated in a large number of studies. However, evidence is difficult to interpret and compare across studies due to variations in the outcomes measured by researchers. In a study looking at outcomes reported in PPH trials published between 1997 and 2015, 121 trials for prevention of PPH used 68 different primary outcomes. 3 The most commonly reported outcome was assessment of blood loss, with more than ten different cut-offs specified at times ranging from 30 minutes to 48 hours. There were few data on short-and long-term morbidity or mortality, and few patient-reported outcomes.
Reduction in maternal mortality is part of the Sustainable Development Goals set by the United Nations. 1 One strategy for achieving this is to ensure that the most effective evidence-based therapies are used to manage PPH, and that global standards follow evidence-based guidelines. 1 Recommendations can only be robust if they are based on good-quality evidence, where interventions are compared using indicators that are standardised and that are important measures of wellbeing.
The aim of this project was to develop consensus among international stakeholders on a set of core outcomes that should be used in trials and systematic reviews to evaluate (1) preventive interventions and (2) therapeutic interventions for women with PPH. A secondary aim was to provide guidance on how to report these core outcomes.
Methods
The project was registered prospectively with the Core Outcome Measures in Effectiveness Trials (COMET) initiative 4 and funded by the British Medical Association. The protocol was peer-reviewed by the COMET team and funding body. Ethics approval was not required. 5 The manuscript has been reported in line with the core outcome sets (COS)-STAR guidelines for COS reporting. 6 Methods are summarised in Figure S1 and further details are available in Appendix S1.
The Steering Committee included two obstetricians (SM, ZA), a midwife (AC), and two methodologists/statisticians with expertise in development of COS (JK, PW). A Scientific Advisory Group (SAG) was set up to provide multidisciplinary expert input and an international perspective (16 members from ten countries and seven stakeholder groups; Appendix S1). Seven stakeholder groups were agreed a priori to be relevant to the project (obstetricians, midwives, anaesthetists, haematologists, neonatologists, health strategists/methodologists, and women's representatives).
Identification of participants for the Delphi survey
Our aim was to involve as many participants as possible, with a minimum of ten in each stakeholder group to allow numbers to be meaningful, taking into account possible attrition in Round 2. 7 The same participants were asked to take both the prevention and treatment PPH surveys. Participants were identified from published trial reports and Cochrane reviews on PPH. Invitations were also sent through the CoRe Outcomes in Women's and Newborn health (CROWN) Initiative journal editors mailing list. 8 Women's representatives were invited through the National Childbirth Trust parent support group (UK) and personal contacts. Further invitations to stakeholders were sent out by snowballing with suggestions from the SAG, authors contacted and targeted participants. The SAG also took a modified Delphi survey separately. This was a methodological investigation to assess the impact of group size and number of panels on selection of outcomes for a COS, and will be the subject of a separate paper.
Identification of outcomes
To identify outcomes relevant to PPH, two systematic reviews of randomised trials were undertaken -one evaluating interventions for prevention of PPH (NA and ZA), the other, treatment of PPH (SM and ZA; details in Appendix S1). All published outcomes were considered for inclusion in the COS.
The reviews identified 121 randomised trials with 160 different outcomes for prevention of PPH and 16 randomised controlled trials with 95 different outcomes for treatment of PPH. Outcomes were classified under overarching domains (blood loss assessment, mortality and morbidity, use of additional interventions and resources, women's and clinicians' views, adverse outcomes, and neonatal outcomes). Duplicate outcomes were removed, similar outcomes were combined, and variations in methods of reporting each outcome were noted (Tables S1 and S2 ). Two outcomes, women's and healthcare professionals' views, were added by the Steering Committee. A total of 35 outcomes for prevention of PPH and 31 outcomes for treatment of PPH were entered into Round 1 of the Delphi.
Delphi survey
A two-round, anonymised electronic Delphi survey was designed on DELPHIMANAGER 9 to obtain consensus on the importance of each outcome among stakeholders. It was decided a priori that results of the Delphi would be used to inform the face-to-face stakeholder meeting where a final COS would be agreed.
Each outcome was listed in the survey with its plain language summary. Participants were asked to rate the importance of each outcome between 1 and 9 on a Likert scale, with 1-3 being 'not important', 3-6 being 'important but not critical' and 7-9 being 'critically important' to report in trials, or select unable to comment. This scale is recommended by the Grading of Recommendations Assessment, Development and Evaluation working group. 10 Participants were invited to suggest additional outcomes for consideration for the COS in Round 1 using free-text responses.
Potential participants were invited to register for the study via e-mail, and the Delphi survey was e-mailed to those who registered. The closing date was set 4 weeks after each round and an e-mail reminder was sent on days 14, 21, and 28. Nonresponders in Round 1 were not invited to participate in Round 2. Nonresponders in Round 2 were sent additional emails to improve response rate.
In Round 2, participants were able to view anonymised results from the first round, presented as the distribution of scores for each outcome in each stakeholder group separately. This allowed participants to reflect on their choices before completing the second round of the survey. Additional relevant outcomes suggested by participants in Round 1 were added to Round 2 (16 for prevention and 18 for treatment; Figures S2 and S3) .
We defined consensus for the Delphi a priori based on guidance in The COMET Handbook. 7 For inclusion in the COS, outcomes required at least 70% of participants in each stakeholder group to score the outcome as critically important and < 15% to score the outcome as not important. Outcomes excluded from the COS required at least 70% of participants in each stakeholder group to score the outcome as not important and < 15% to score the outcome as 'critical'. If outcomes did not meet either criterion they were classified as outcomes with no consensus.
Face-to-face meeting
The final phase of the project was a face-to-face consensus meeting (Liverpool, UK, 16-17 August 2016). Twenty-five people attended the meeting, and each stakeholder group was represented: five obstetricians, three midwives, four women's representatives, five health strategist/methodologists, one anaesthetist, one haematologist, and one neonatologist (Appendix S1). Findings of the survey were presented and participants were given an opportunity to discuss each outcome. Consideration was given as to whether the outcome was relevant in all settings and for all women recruited. Outcomes could be re-named or reconfigured if there was full consensus at the meeting to do so. Participants then scored each outcome between 1 and 9 on the Likert scale, for inclusion or exclusion in the COS with an anonymous voting system using electronic keypads. Consensus at the meeting required a majority of 70% of participants to score the outcome as critically important (7-9) for its inclusion in the COS.
Methodology for how to report outcomes
Consensus on how to report the COS outcomes was developed on Day 2 of the meeting by an Expert Committee (n = 20; Appendix S1). The aim was not to create new definitions but to select a preferred method of reporting the outcome among existing methods in published literature where possible and to make research recommendations where this was not possible.
We used recommended standards on how to report summary results for trial reporting 11 and considered the specific metric on how to measure the outcome, the method of data aggregation (continuous or categorical) and the time frame in which to measure the outcome. Variations in outcome reporting were presented and expert presentations were delivered. Options were discussed, and scored. Consensus was defined a priori as > 70% of participants voting for a preferred option of reporting, and majority view was defined as > 50% of participants preferring one option from among the top three options, thereby indicating the strength of the recommendation. (Table 1) . Overall, 77% of those who took the survey had exposure to PPH either through personal experience or through caring for women who had experienced PPH. Among women's representatives, 41% had experienced a PPH.
Results

Survey participants came from 36 different countries (Fig
Assessment of outcomes for the prevention and treatment of PPH COS is shown in Figure 1 . Delphi consensus was reached for including five outcomes in the COS for prevention of PPH and ten outcomes in the COS for treatment of PPH. No outcomes fulfilled criteria for exclusion. There was no consensus on the remaining outcomes. After discussing these results at the face-to face meeting, the final COS included nine outcomes for prevention and 12 outcomes for treatment of PPH. At least one outcome from each domain was included in both COS, and there was significant overlap in outcomes included between the two COS.
PPH prevention COS
For the evaluation of interventions for prevention of PPH, the final COS outcomes are presented in Table 2 . At the stakeholder meeting, all outcomes that met the Delphi consensus criteria were included in the COS except for hysterectomy. Although stakeholders at the meeting agreed that hysterectomy was an important outcome, it was not felt to be critically important in the context of trials for PPH prevention because it is a very rare event. Although rare but critically important outcomes are also important to include in a COS, and the outcome 'maternal mortality' has been included, there was consensus that the PPH prevention COS would be more informative if it captured other measures of maternal morbidity for which data were more likely to be available from trials rather than having a COS with few data available for multiple outcomes. Blood loss was thought to be an important outcome for PPH trials to report, although difficulties in assessing it were acknowledged. Four additional outcomes were included in the PPH prevention COS subsequent to stakeholder discussions and voting. Two of these outcomes, 'use of blood transfusion' and 'use of additional uterotonics' were borderline for inclusion in the Delphi survey ( Table 2 ). The outcomes 'transfer to Intensive Therapy Unit' and 'transfer to a higher facility' in the Delphi were reconfigured at the stakeholder meeting to 'transfer to a higher level of care' to capture data on an escalation in the level of care required for the woman, which, it was recognised, would depend on the initial setting of the woman. There was also consensus among stakeholders at the meeting that patient-reported outcomes, although not included in the Delphi consensus, 
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Delphi Round 1 outcomes = 35
Outcomes added = 16 Suggested by SAG & Delphi participants
Prevention of PPH
Total outcomes = 161 From systematic reviews: 160 Added by steering group = 1 Delphi Round 2 outcomes = 51 Excluded=15, non-specific/not relevant 146 outcomes grouped into 7 domains Similar outcomes combined (n = 35) Consensus 'in' = 5
No consensus = 46 Consensus 'out' = 0
Final core outcome set = 9 -7 outcomes included as presented in Delphi -2 outcomes reconfigured were important to include in the COS, and this was strongly advocated by the women's representatives. It was felt that these should capture a woman's sense of wellbeing, as well as acceptability and satisfaction with the intervention. Among outcomes in the neonatal domain, there was consensus that breastfeeding would be an important outcome as a PPH may impact on a woman's wellness and ability to establish or maintain breastfeeding if she intended to breastfeed, or there could be a potential impact of the intervention on breast milk itself.
PPH treatment COS
For the evaluation of interventions for treatment of PPH, the final COS is presented in Table 3 . Nine of the ten outcomes that met the Delphi consensus criteria were included in the final COS. Two very similar outcomes -'shock' and 'maternal resuscitation due to shock' -were both included by the Delphi survey. Hence, consensus at the stakeholder meeting was to include 'shock' only in preference to 'maternal resuscitation due to shock' as the latter would be more complex to measure. The outcome disseminated intravascular coagulation was renamed as coagulopathy based on recommendations by haematologists because coagulopathy is the more accurate term; disseminated intravascular coagulation does not have a validated definition in PPH and constitutes only a small subset of coagulopathies associated with PPH. Multiple organ failure was renamed as 'any organ dysfunction', in line with the recommendations of the World Health Organization (WHO) on how to capture severe pregnancy complications including organ dysfunction in the WHO near-miss approach for maternal health. 12 A number of outcomes in the Delphi survey aimed at capturing failure of initial treatment -for example, use of additional medical or advanced surgical interventions such as balloon insertion or uterine artery embolisation or ligation. However, at the meeting it was recognised that type of escalation of therapy would depend on the trial intervention itself -medical or surgical. Therefore, these outcomes were reconfigured into the outcome 'Use of any additional haemostatic intervention' to capture failure of the trial intervention itself, as this would be applicable to all trials, regardless of the intervention they were evaluating. The other outcomes added were a woman's sense of wellbeing and acceptability and satisfaction with the intervention, and breastfeeding as specified above in the prevention of PPH COS.
How to report COS outcomes
The Expert Committee Recommendations on how to report the COS outcomes are presented in Table 4 , along with explanations. Most recommendations were agreed by consensus. Those agreed by majority view included reporting of hysterectomies specifically carried out to stop PPH, to avoid confounding data with hysterectomies carried out prophylactically or for other indications. For time frames for measuring outcomes, there was consensus that in the context of randomised trials, outcome data should be collected from the point of randomisation. The time limit up to which outcomes should be measured was left to triallists for most outcomes, to accommodate for local protocols and resource availability. However, a majority view recommendation was put forward for blood loss to be assessed (measured or estimated) up to cessation of active bleeding, as this is an area where standardisation is particularly lacking and time-frame selection is likely to impact on data significantly. For hysterectomy, the majority recommendation was to report it at least up to hospital discharge as most hysterectomies are likely to occur by that time in the context of PPH.
For the patient-reported outcomes and breastfeeding, it was felt by the stakeholder groups that further work was needed to develop tools to capture what aspects of these outcomes were most important to women in the context of a PPH.
Discussion
Main findings
Consensus on PPH COS was developed among an international panel of stakeholders through a Delphi survey and face-to-face meeting. For the evaluation of interventions for prevention of PPH, nine core outcomes were selected and for treatment of PPH, 12 core outcomes were selected. Expert committee recommendations where developed on how to report each outcome where possible, and a research agenda was set for two outcomes where this was not possible.
Strengths and limitations
This project has several strengths. First, the methodology was defined a priori based on guidelines by the COMET Initiative. 7 The Delphi exercise has the advantage of including views of a larger number of geographically distant participants. Participants in the Delphi were still able to consider the views of other stakeholder groups in Round 2, to reconsider their opinion without being overly influenced by domineering individuals. Results were further refined at the face-to-face meeting, which allowed for rich discussions as well as the ability to debate and persuade others. Second, stakeholders came from a range of relevant specialties. Importantly, consumer representatives, who are sometimes overlooked in similar projects, 23, 24 were included at all stages of the process. There was representation from both those who had and had not experienced PPH. Our parent representatives impacted the final COS outcomes by influencing other stakeholders at the face-to-face meeting to Various methods have been used to assess shock and there is growing evidence on use of shock index in obstetric patients. 12, [17] [18] [19] [20] [21] Evidence from prospective studies is awaited before recommendations can be made on how to best assess shock. 22 
Maternal death Prevention & Treatment
Number of maternal deaths in each group from all causes and maternal deaths from PPH, from randomisation up to time decided by triallists.** Maternal death, as defined by the World Health Organization. 12 
Blood transfusion Prevention & Treatment
Number of women with any RBC blood transfusion in each group AND mean or median* RBC units transfused in each group from randomisation up to time decided by triallists. For treatment COS only, number of women with any other blood products in each group should also be reported.
RBC blood transfusion may also include cell salvage.
Other blood products include platelets, fresh frozen plasma, and cryoprecipitate.
Transfer to higher level of care
Prevention & Treatment
Number of women transferred to a higher level of care in each group from randomisation up to time decided by triallists.
A higher level of care may include transfer to hospital, higher facility, intensive care unit or specialist ward depending on trial setting. 6. Use of additional haemostatic intervention
Prevention
Number of women in whom any additional uterotonics were used in each group from randomisation up to time decided by triallists.
The additional haemostatic intervention will depend on what the trial intervention is. This may include additional uterotonics in trials evaluating medical treatments or surgical methods in trials evaluating more invasive methods such as balloon tamponade. The aim of this outcome is to capture failure of the trial intervention, and need for use of other treatments.
Treatment
Number of women in whom any additional haemostatic intervention (medical or surgical) was used in each group from randomisation up to time decided by triallists. 7. Hysterectomy Treatment Number of women who had a hysterectomy to stop bleeding in each group, from randomisation, at least up to hospital discharge.
Hysterectomies performed specifically to stop bleeding should be reported to avoid confounding data with hysterectomies performed prophylactically or for other indications.
Coagulopathy
Treatment Number of women with coagulopathy in each group from randomisation up to time decided by triallists.
Coagulopathy should be defined as specified in annex 1 of the document WHO near miss approach for maternal health. Organ dysfunction should be defined as specified in the document WHO near-miss approach for maternal health. 12 
Adverse effects Prevention & Treatment
Number of women (and babies if relevant) with side effects and serious adverse effects in each group.
Side effects and serious adverse effects will be intervention specific, therefore should be defined by triallists as appropriate.
Breastfeeding Prevention & Treatment
There is a need to explore in future research studies how to best report this outcome.
Aspects considered important were initiation and maintenance of breastfeeding. 12. Patientreported outcomes
Prevention & Treatment
There is a need to explore in future research studies how to best report these outcomes.
Outcomes that need qualification are a woman's sense of wellbeing, acceptability and satisfaction with the intervention. Further research is required with women's views on how to best report these.
COS, core outcome sets; PPH, postpartum haemorrhage. *Report mean or median depending on data distribution. **Agreed by majority view rather than consensus.
include patient-reported outcomes. Third, there was representation from a wide range of countries of variable income status in the Delphi and at the face-to-face meeting, so that the COS developed would be applicable across different settings. Fourth, we have developed COS for both prevention and treatment of PPH to cover the full spectrum of PPH intervention trials. It is not surprising that there is significant overlap in outcomes selected for the two COS. However, the PPH treatment COS appropriately includes more outcomes that capture significant maternal morbidity in the presence of an established PPH. And finally, a COS often tells researchers what outcomes to use, but not how to report them, making it difficult to achieve adequate standardisation; we have developed Expert Committee Recommendations on how to report the outcomes selected for PPH COS to provide better guidance to researchers. The limitations of this project are that outcomes were obtained largely from systematic reviews and participants in the Delphi exercise; we did not conduct formal interviews with women. Second, we asked participants to identify one key stakeholder group to which they belonged. Some participants may have belonged to more than one stakeholder group and this may have influenced how they scored outcomes, but data are not available to explore this further. Third, representations from each stakeholder group were not equal; this may have impacted on the outcomes selected. Finally, although we have developed guidance on how to report COS outcomes, these recommendations are from a small group of experts, and have not been subjected to the same rigorous Delphi process in a large group. However, it is debatable whether a Delphi process is the optimum method for developing consensus on how to report outcomes. More complex discussions may need to be undertaken for consensus on measurement instruments by stakeholders who may be different from those partaking in the 'what to measure' Delphi. Generic methodological guidelines on how to select standardised instrument measures for outcomes have recently been published. 25 They recommend identifying all possible measurement instruments for an outcome, and selecting one with high quality of evidence for good validity and internal consistency, that is feasible to measure in the target population. These guidelines have not yet been applied prospectively for COS in maternal health. Our systematic reviews identified the different ways in which COS outcomes have been reported, and the feasibility of applying the instruments in an international setting was considered when making recommendations on how to report outcomes. Although validity may be excellent for the more objective outcomes included in the COS, such as units of blood transfusion or maternal death, measurement tools for other outcomes such as blood loss are well known for their poor accuracy.
Interpretation
To our knowledge, there is no other published COS for PPH. These COS include outcomes that capture meaningful morbidity (shock, hysterectomy, organ dysfunction) and mortality. They also include outcomes with high event rates upon which sample size calculations could be based for smaller studies (blood loss, use of additional uterotonics, blood transfusion). Resource use may be assessed through use of additional interventions and level of care such as Intensive Therapy Unit' use. Patient-reported outcomes (wellbeing and satisfaction) and breastfeeding are also captured but require further qualitative research on how best to measure these outcomes. Until further data are available, we would encourage researchers to clearly report the measures that they have used.
Although these outcomes aim to assess the impact of interventions evaluated on severity of PPH, some outcomes may be influenced by local practices. For example, thresholds used for transfusing blood or transferring a woman for higher level of care may vary across trial settings and studies. For such outcomes we would encourage authors to interpret results bearing the potential impact of local practices in mind.
We would recommend that researchers evaluating interventions for PPH should report these COS outcomes as a minimum, along with any other outcomes of interest to their study. Where these COS are not reported, researchers are encouraged to provide an explanation, for transparency and to reduce the risk of reporting bias. Future trials evaluating interventions for PPH should report any barriers identified to data collection for these COS outcomes. COS may be updated to provide guidance in response to such feedback.
Conclusions
The PPH COS, developed through an international multidisciplinary effort, will help standardise outcome reporting in this area, and facilitate comparison of data across studies, to guide clinical practice. We recommend that researchers evaluating interventions for PPH prevention and treatment should report these COS outcomes as a minimum, along with any other outcomes of interest. Further work is needed on how to best to report women's sense of wellbeing, acceptability and satisfaction with the intervention and breastfeeding in the context of PPH.
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